表紙:乾癬治療薬の世界市場(~2026年):治療クラス別、治療タイプ別、作用メカニズム別、投与経路別、流通経路別、用途別、地域別の市場調査、予測、COVID-19の累積的な影響
市場調査レポート
商品コード
1035742

乾癬治療薬の世界市場(~2026年):治療クラス別、治療タイプ別、作用メカニズム別、投与経路別、流通経路別、用途別、地域別の市場調査、予測、COVID-19の累積的な影響

Psoriasis Drugs Market Research Report by Therapeutic Class, by Type of Treatment, by Mechanism of Action, by Route of Administration, by Distribution Channel, by Application, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

出版日: | 発行: 360iResearch LLP | ページ情報: 英文 197 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.86円
乾癬治療薬の世界市場(~2026年):治療クラス別、治療タイプ別、作用メカニズム別、投与経路別、流通経路別、用途別、地域別の市場調査、予測、COVID-19の累積的な影響
出版日: 2021年11月04日
発行: 360iResearch LLP
ページ情報: 英文 197 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

乾癬治療薬の市場規模は、2020年に69億3,278万米ドル、2021年に77億3,283万米ドルとなり、年平均成長率(CAGR)11.87%で成長し、2026年までに135億9,520万米ドルとなると予想されています。

当レポートでは世界の乾癬治療薬市場を調査し、市場の概要、市場の促進要因・抑制要因の分析、市場機会、COVID-19の影響、治療クラス・治療タイプ・作用メカニズム・投与経路・流通経路・用途・地域別の市場分析、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

第1章 序文

  • 調査の目的
  • 市場セグメンテーションとカバレッジ
  • 調査のために考慮された年
  • 通貨と価格
  • 言語
  • 制限事項
  • 仮定
  • 利害関係者

第2章 調査手法

  • 定義:調査目的
  • 決定:調査デザイン
  • 準備:調査機器
  • 収集:データソース
  • 分析:データの解釈
  • 策定:データ検証
  • 公開:調査レポート
  • 繰り返し:レポートの更新

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場の洞察

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
    • 課題
  • COVID-19の累積的影響

第6章 治療クラス別、乾癬治療薬市場

  • インターロイキン阻害剤
  • 腫瘍壊死因子阻害剤

第7章 治療タイプ別、乾癬治療薬市場

  • 生物学的医薬品
  • 小分子全身薬
  • 熱帯療法

第8章 作用メカニズム別、乾癬治療薬市場

  • インターロイキン阻害剤
  • PDE4阻害剤
  • TNFアルファ阻害剤

第9章 投与経路別、乾癬治療薬市場

  • 経口
  • 非経口
  • 局所

第10章 流通チャネル別、乾癬治療薬市場

  • 病院薬局
  • オンライン薬局
  • 小売薬局

第11章 用途別、乾癬治療薬市場

  • 関節炎
  • 紅皮症
  • 滴状
  • 間欠的
  • プラーク
  • 膿疱性

第12章 南北アメリカの乾癬治療薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第13章 アジア太平洋地域の乾癬治療薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ

第14章 欧州、中東・アフリカの乾癬治療薬市場

  • フランス
  • ドイツ
  • イタリア
  • オランダ
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • アラブ首長国連邦
  • 英国

第15章 競合情勢

  • FPNVポジショニングマトリックス
    • 象限
    • 事業戦略
    • 製品の満足度
  • 市場ランキング分析
  • キープレーヤー別市場シェア分析
  • 競合シナリオ
    • 合併と買収
    • 合意、コラボレーション、およびパートナーシップ
    • 新製品の発売と強化
    • 投資と資金調達
    • 賞、表彰、拡大

第16章 企業のユーザビリティプロファイル

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Biogen Idec
  • C.H. Boehringer Sohn AG & Ko. KG
  • Celgene Corporation
  • Dr.Reddy's Laboratories
  • Eli Lilly and Company
  • Forward Pharma
  • Johnson & Johnson Services, Inc.
  • Leo Pharma AS
  • Merck & Co., Inc.
  • Merck and Co. Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Stiefel Laboratories Inc.
  • Sun Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Company Limited
  • UCB SA

第17章 付録

  • ディスカッションガイド
  • ライセンスと価格
図表

LIST OF FIGURES

  • FIGURE 1. GLOBAL PSORIASIS DRUGS MARKET: RESEARCH PROCESS
  • FIGURE 2. GLOBAL PSORIASIS DRUGS MARKET: MARKET DYNAMICS
  • FIGURE 3. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2020 VS 2026 (%)
  • FIGURE 4. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2020 VS 2026 (USD MILLION)
  • FIGURE 5. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2026
  • FIGURE 6. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2026 (USD MILLION)
  • FIGURE 7. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 8. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITOR, 2018-2026 (USD MILLION)
  • FIGURE 9. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITOR, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 10. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2020 VS 2026 (%)
  • FIGURE 11. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2020 VS 2026 (USD MILLION)
  • FIGURE 12. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2026
  • FIGURE 13. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY BIOLOGIC DRUGS, 2018-2026 (USD MILLION)
  • FIGURE 14. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY BIOLOGIC DRUGS, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 15. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULE SYSTEMIC DRUGS, 2018-2026 (USD MILLION)
  • FIGURE 16. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULE SYSTEMIC DRUGS, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 17. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TROPICAL THERAPIES, 2018-2026 (USD MILLION)
  • FIGURE 18. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TROPICAL THERAPIES, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 19. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2020 VS 2026 (%)
  • FIGURE 20. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2020 VS 2026 (USD MILLION)
  • FIGURE 21. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2026
  • FIGURE 22. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2026 (USD MILLION)
  • FIGURE 23. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 24. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, 2018-2026 (USD MILLION)
  • FIGURE 25. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 26. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TNF ALPHA INHIBITORS, 2018-2026 (USD MILLION)
  • FIGURE 27. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TNF ALPHA INHIBITORS, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 28. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 VS 2026 (%)
  • FIGURE 29. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 VS 2026 (USD MILLION)
  • FIGURE 30. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2026
  • FIGURE 31. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2026 (USD MILLION)
  • FIGURE 32. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 33. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2026 (USD MILLION)
  • FIGURE 34. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 35. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2026 (USD MILLION)
  • FIGURE 36. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 37. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2020 VS 2026 (%)
  • FIGURE 38. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2020 VS 2026 (USD MILLION)
  • FIGURE 39. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2026
  • FIGURE 40. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2026 (USD MILLION)
  • FIGURE 41. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 42. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2026 (USD MILLION)
  • FIGURE 43. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 44. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2026 (USD MILLION)
  • FIGURE 45. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 46. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2020 VS 2026 (%)
  • FIGURE 47. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2020 VS 2026 (USD MILLION)
  • FIGURE 48. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2026
  • FIGURE 49. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ARTHRITIS, 2018-2026 (USD MILLION)
  • FIGURE 50. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ARTHRITIS, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 51. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ERYTHRODERMIC, 2018-2026 (USD MILLION)
  • FIGURE 52. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ERYTHRODERMIC, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 53. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GUTTATE, 2018-2026 (USD MILLION)
  • FIGURE 54. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GUTTATE, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 55. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTERTRIGINOUS, 2018-2026 (USD MILLION)
  • FIGURE 56. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTERTRIGINOUS, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 57. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY NAIL, 2018-2026 (USD MILLION)
  • FIGURE 58. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY NAIL, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 59. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PLAQUE, 2018-2026 (USD MILLION)
  • FIGURE 60. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PLAQUE, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 61. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PUSTULAR, 2018-2026 (USD MILLION)
  • FIGURE 62. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PUSTULAR, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 63. AMERICAS PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 64. ARGENTINA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 65. BRAZIL PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 66. CANADA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 67. MEXICO PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 68. UNITED STATES PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 69. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 70. AUSTRALIA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 71. CHINA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 72. INDIA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 73. INDONESIA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 74. JAPAN PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 75. MALAYSIA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 76. PHILIPPINES PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 77. SINGAPORE PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 78. SOUTH KOREA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 79. TAIWAN PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 80. THAILAND PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 81. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 82. FRANCE PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 83. GERMANY PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 84. ITALY PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 85. NETHERLANDS PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 86. QATAR PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 87. RUSSIA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 88. SAUDI ARABIA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 89. SOUTH AFRICA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 90. SPAIN PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 91. UNITED ARAB EMIRATES PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 92. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 93. GLOBAL PSORIASIS DRUGS MARKET: FPNV POSITIONING MATRIX
  • FIGURE 94. GLOBAL PSORIASIS DRUGS MARKET: SHARE, BY KEY PLAYER, 2020
  • FIGURE 95. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL PSORIASIS DRUGS MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL PSORIASIS DRUGS MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2026 (USD MILLION)
  • TABLE 4. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 5. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITOR, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 6. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2026 (USD MILLION)
  • TABLE 7. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY BIOLOGIC DRUGS, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 8. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULE SYSTEMIC DRUGS, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 9. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TROPICAL THERAPIES, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 10. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD MILLION)
  • TABLE 11. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 12. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 13. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TNF ALPHA INHIBITORS, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 14. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD MILLION)
  • TABLE 15. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 16. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 17. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 18. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD MILLION)
  • TABLE 19. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 20. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 21. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 22. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
  • TABLE 23. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ARTHRITIS, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 24. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ERYTHRODERMIC, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 25. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GUTTATE, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 26. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTERTRIGINOUS, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 27. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY NAIL, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 28. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PLAQUE, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 29. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PUSTULAR, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 30. AMERICAS PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 31. ARGENTINA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 32. BRAZIL PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 33. CANADA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 34. MEXICO PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 35. UNITED STATES PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 37. AUSTRALIA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 38. CHINA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 39. INDIA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 40. INDONESIA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 41. JAPAN PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 42. MALAYSIA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 43. PHILIPPINES PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 44. SINGAPORE PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 45. SOUTH KOREA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 46. TAIWAN PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 47. THAILAND PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 48. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 49. FRANCE PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 50. GERMANY PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 51. ITALY PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 52. NETHERLANDS PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 53. QATAR PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 54. RUSSIA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 55. SAUDI ARABIA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 56. SOUTH AFRICA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 57. SPAIN PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 58. UNITED ARAB EMIRATES PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 59. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 60. GLOBAL PSORIASIS DRUGS MARKET: SCORES
  • TABLE 61. GLOBAL PSORIASIS DRUGS MARKET: BUSINESS STRATEGY
  • TABLE 62. GLOBAL PSORIASIS DRUGS MARKET: PRODUCT SATISFACTION
  • TABLE 63. GLOBAL PSORIASIS DRUGS MARKET: RANKING
  • TABLE 64. GLOBAL PSORIASIS DRUGS MARKET: SHARE, BY KEY PLAYER, 2020
  • TABLE 65. GLOBAL PSORIASIS DRUGS MARKET: MERGER & ACQUISITION
  • TABLE 66. GLOBAL PSORIASIS DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 67. GLOBAL PSORIASIS DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 68. GLOBAL PSORIASIS DRUGS MARKET: INVESTMENT & FUNDING
  • TABLE 69. GLOBAL PSORIASIS DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 70. GLOBAL PSORIASIS DRUGS MARKET: LICENSE & PRICING
目次
Product Code: MRR-434CCDA051BC

The Global Psoriasis Drugs Market size was estimated at USD 6,932.78 million in 2020 and expected to reach USD 7,732.83 million in 2021, at a CAGR 11.87% to reach USD 13,595.20 million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Psoriasis Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:

  • Based on Therapeutic Class, the market was studied across Interleukin Inhibitors and Tumor Necrosis Factor Inhibitor.
  • Based on Type of Treatment, the market was studied across Biologic Drugs, Small Molecule Systemic Drugs, and Tropical Therapies.
  • Based on Mechanism of Action, the market was studied across Interleukin Inhibitors, PDE4 Inhibitors, and TNF Alpha Inhibitors.
  • Based on Route of Administration, the market was studied across Oral, Parenteral, and Topical.
  • Based on Distribution Channel, the market was studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Application, the market was studied across Arthritis, Erythrodermic, Guttate, Intertriginous, Nail, Plaque, and Pustular.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Psoriasis Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor's strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Psoriasis Drugs Market, including AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bausch Health Companies Inc., Biogen Idec, C.H. Boehringer Sohn AG & Ko. KG, Celgene Corporation, Dr.Reddy's Laboratories, Eli Lilly and Company, Forward Pharma, Johnson & Johnson Services, Inc., Leo Pharma AS, Merck & Co., Inc., Merck and Co. Inc., Novartis International AG, Pfizer Inc., Stiefel Laboratories Inc., Sun Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company Limited, and UCB SA.

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Psoriasis Drugs Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Psoriasis Drugs Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Psoriasis Drugs Market?
  • 4. What is the competitive strategic window for opportunities in the Global Psoriasis Drugs Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Psoriasis Drugs Market?
  • 6. What is the market share of the leading vendors in the Global Psoriasis Drugs Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Psoriasis Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Define: Research Objective
  • 2.3. Determine: Research Design
  • 2.4. Prepare: Research Instrument
  • 2.5. Collect: Data Source
  • 2.6. Analyze: Data Interpretation
  • 2.7. Formulate: Data Verification
  • 2.8. Publish: Research Report
  • 2.9. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of psoriasis
      • 5.1.1.2. Rising geriatric population coupled with growing prevalence of plaque psoriasis and psoriatic arthritis
      • 5.1.1.3. Ease of process of approval of psoriasis drugs
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing awareness regarding treatment and rising demand for improved healthcare infrastructure
      • 5.1.3.2. Adoption of technologically advanced non-invasive or minimally invasive psoriasis treatment procedures
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects of the medication
  • 5.2. Cumulative Impact of COVID-19

6. Psoriasis Drugs Market, by Therapeutic Class

  • 6.1. Introduction
  • 6.2. Interleukin Inhibitors
  • 6.3. Tumor Necrosis Factor Inhibitor

7. Psoriasis Drugs Market, by Type of Treatment

  • 7.1. Introduction
  • 7.2. Biologic Drugs
  • 7.3. Small Molecule Systemic Drugs
  • 7.4. Tropical Therapies

8. Psoriasis Drugs Market, by Mechanism of Action

  • 8.1. Introduction
  • 8.2. Interleukin Inhibitors
  • 8.3. PDE4 Inhibitors
  • 8.4. TNF Alpha Inhibitors

9. Psoriasis Drugs Market, by Route of Administration

  • 9.1. Introduction
  • 9.2. Oral
  • 9.3. Parenteral
  • 9.4. Topical

10. Psoriasis Drugs Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Psoriasis Drugs Market, by Application

  • 11.1. Introduction
  • 11.2. Arthritis
  • 11.3. Erythrodermic
  • 11.4. Guttate
  • 11.5. Intertriginous
  • 11.6. Nail
  • 11.7. Plaque
  • 11.8. Pustular

12. Americas Psoriasis Drugs Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Psoriasis Drugs Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand

14. Europe, Middle East & Africa Psoriasis Drugs Market

  • 14.1. Introduction
  • 14.2. France
  • 14.3. Germany
  • 14.4. Italy
  • 14.5. Netherlands
  • 14.6. Qatar
  • 14.7. Russia
  • 14.8. Saudi Arabia
  • 14.9. South Africa
  • 14.10. Spain
  • 14.11. United Arab Emirates
  • 14.12. United Kingdom

15. Competitive Landscape

  • 15.1. FPNV Positioning Matrix
    • 15.1.1. Quadrants
    • 15.1.2. Business Strategy
    • 15.1.3. Product Satisfaction
  • 15.2. Market Ranking Analysis
  • 15.3. Market Share Analysis, By Key Player
  • 15.4. Competitive Scenario
    • 15.4.1. Merger & Acquisition
    • 15.4.2. Agreement, Collaboration, & Partnership
    • 15.4.3. New Product Launch & Enhancement
    • 15.4.4. Investment & Funding
    • 15.4.5. Award, Recognition, & Expansion

16. Company Usability Profiles

  • 16.1. AbbVie Inc.
  • 16.2. Amgen Inc.
  • 16.3. AstraZeneca PLC
  • 16.4. Bausch Health Companies Inc.
  • 16.5. Biogen Idec
  • 16.6. C.H. Boehringer Sohn AG & Ko. KG
  • 16.7. Celgene Corporation
  • 16.8. Dr.Reddy's Laboratories
  • 16.9. Eli Lilly and Company
  • 16.10. Forward Pharma
  • 16.11. Johnson & Johnson Services, Inc.
  • 16.12. Leo Pharma AS
  • 16.13. Merck & Co., Inc.
  • 16.14. Merck and Co. Inc.
  • 16.15. Novartis International AG
  • 16.16. Pfizer Inc.
  • 16.17. Stiefel Laboratories Inc.
  • 16.18. Sun Pharmaceutical Industries Ltd
  • 16.19. Takeda Pharmaceutical Company Limited
  • 16.20. UCB SA

17. Appendix

  • 17.1. Discussion Guide
  • 17.2. License & Pricing